Study on Biomarkers of Immune-Related Adverse Events
ConditionImmune-Related Adverse Events
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHuazhong University of Science and Technology
About this trial
1. To identify biomarkers of immune-related adverse events; 2. To develop a predictive model for immune-related adverse events.
Eligibility criteria
Qualifiers
Age >18 years;
Karnofsky Performance Status (KPS) >60;
Expected to receive at least one cycle of immune checkpoint inhibitor therapy;
Expected survival >6 months.
Disqualifiers
Prior treatment with immune checkpoint inhibitors;
Active autoimmune diseases (including systemic lupus erythematosus, inflammatory bowel disease, rheumatoid arthritis, myasthenia gravis, scleroderma, etc.);
Use of systemic immunosuppressive agents within 14 days prior to enrollment (prednisone >10 mg/day or equivalent);
Inability to provide biological samples.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
440 Participants
are grouped into 1 trial groupLocations
Sponsors and collaborators
Huazhong University of Science and Technology
Lead sponsor
Tongji Hospital
Sponsor institution
Source ClinicalTrials.gov